期刊文献+

承德地区幽门螺杆菌耐药性研究分析 被引量:3

Analysis of Antibacterail Resistance of 108 Strains of Helicobacter Pylori in Area of Chengde in Hebei of China
下载PDF
导出
摘要 目的:通过分析承德地区幽门螺杆菌(helicobacter pylori,H .pylori)临床分离珠对多种抗菌药物的敏感性,指导临床对于 H pylori根除治疗时的药物选择,提高根除率。方法用Kirby-Bauer药敏纸片法对108珠H pylori分别进行9种抗生素的药敏试验,并对药敏结果进行分析,得出相应的结果。结果 H pylori对阿莫西林/克拉维酸钾、阿莫西林的敏感率为100%,对甲硝唑、呋喃唑酮、克拉霉素、左氧氟沙星、四环素、米诺环素、氨苄西林的敏感率为76.9%、18.5%、9.3%、40.7%、8.3%、11.1%、37.8%。结论承德地区H pylori对阿莫西林/克拉维酸钾、阿莫西林、克拉霉素的敏感率高,可推荐为临床首选药物。对甲硝唑、左氧氟沙星、氨苄西林敏感率较低,不建议常规使用。 Objective Through the analysis of clinical isoates of helicobacter pylori(H pylori)Chengde beads antimicrobial susceptibility to a variety of clinical drug of choice for treatment of H pylori eradication,to improve eradication rates.Methods Susceptibility using the Kirby-auer disk dif usion method against 108 clincial isolates of H pylori pearl beads were performed in nine of antimicrobial susceptibility testing,and analyze the results.Results The profit sensitivity rate of H pylori to amocxicil in/ciavulanate、amoxicil in were100%to metronidazole、furazolidone、clarithromycin、levpfloxacin、minocycline、tetracycline a-nd ampicil in was76.9%、18.5%、9.3%、40.7%、8.3%、11.1%、37.8%.Concluion Chengde H pylori amoxicil ion/clavulanate potassium,amoxicil in sensitive rate,can be recommend-ed for clinical drug of choice,mertonidazole、levofloxacin、minocycline sensitive lower rate,was not recommended for routine use.
作者 李立文 孙学慧 李建辉 LI Li-wen;SUN Xue-hui;LI Jian-hui(Chengde City Central Hospital,Chengde 067000,Hebei,China)
机构地区 承德市中心医院
出处 《医学信息(医学与计算机应用)》 2014年第10期140-140,141,共2页 Medical Information
关键词 承德地区 幽门螺杆菌 药敏试验 耐药性 Chengdearea Drug sensitive test Antibiotic resistance Hilicobacter pylori
  • 相关文献

参考文献3

二级参考文献41

共引文献46

同被引文献36

  • 1周丽雅,林三仁,丁士刚,黄雪彪,郭长吉,张莉,崔荣丽,金珠,孟灵梅,张静.根除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究[J].中华消化杂志,2005,25(6):324-327. 被引量:87
  • 2Testino G. Gastric preneoplastic changes[J]. Hecemti Prog Med, 2004, 95(5): 239-244.
  • 3Ando T, Ishikawa T, Takagi T, et al. Impact of Helicobacter pylori eradication on circulating adiponectin in humans[J]. Helicobacter, 2013, 18(2): 158-164.
  • 4Fischbach L, Evans E L. Meta-analysis: the effect ofantibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori[J]. Aliment Pharmacol Ther, 2007, 26(3): 343-357.
  • 5Gao W, Cheng H, Hu F, et al. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. [J]. Helicobacter, 2010, 15(5): 460-466.
  • 6Zhou L Y, Zhang J Z, Chen M H, et al. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: A randomized multicenter trial[J]. Am J Gastroenterol, 2014, 109(4): 535-541.
  • 7Graham D Y, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy[J]. Helicobacter, 2007, 12(4): 275-278.
  • 8Heep M, Kist M, Strobel S, et al. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy[J]. Eur J Clin Microbiol lnfect Dis, 2000, 19(7): 538-541.
  • 9Horiki N, Omata F, Uemura M, et al. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan[J]. Helicobacter, 2009, 14(5): 86-90.
  • 10朱振坤,汪金云,王巧燕,等.胃肠病患者幽门螺杆菌感染状况及耐药性分析[J].中华高血压杂志,2014,11(22):83-84.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部